Amendments to the Claims:

The following Listing of Claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (currently amended) A composition comprising:

(a) a drug in a pharmaceutically acceptable solubility-improved form that is a crystalline highly soluble salt form other than the crystalline hydrochloride salt; and

(b) a concentration-enhancing polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methyl cellulose phthalate, and hydroxypropyl methyl cellulose acetate succinate

wherein

said drug alone has an aqueous solubility of up to about 1 to 2 mg/mL; and

~~when said drug is basic, said solubility-improved form has an aqueous solubility of at least two-fold the solubility of the more soluble of the crystalline hydrochloride salt and the crystalline free base drug form; and~~

said composition is not a dispersion and said drug and said polymer are present as particles in a dry physical mixture.

2-28. (cancelled)

29. (previously presented) The composition of claim 1 wherein said drug is selected from antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-lowering agents, decongestants, antihistamines, antitussives, antineoplastics, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, cholesterol-reducing agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial and antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, antibiotics, anti-depressants, and antiviral agents.

30-155. (cancelled)

156. (previously presented) The composition of claim 1, wherein said drug is ziprasidone.

164. (currently amended) A composition comprising:

(a) a drug in a crystalline highly soluble salt form other than the crystalline hydrochloride salt; and

(b) hydroxypropyl methyl cellulose acetate succinate

wherein

said composition is not a dispersion;

said drug alone has an aqueous solubility up to about 1 to 2 mg/mL; and

~~when said drug is basic, said crystalline highly soluble salt form has an aqueous solubility at least two-fold the solubility of the crystalline hydrochloride salt form; and~~

said crystalline highly soluble salt form and said hyroxypropylmethyl cellulose acetate succinate are present as particles in a dry physical mixture.

165. (previously presented) The composition of claim 1 or 164 wherein said crystalline highly soluble salt form is selected from the group consisting of the bromide, acetate, iodide, mesylate, phosphate, maleate, citrate, sulfate, tartrate, and lactate salts.

166. (previously presented) The composition of claim 1 or 164 wherein said crystalline highly soluble salt form is selected from the group consisting of the sodium, calcium, potassium, zinc, magnesium, lithium, aluminum, meglumine, diethanolamine, benzathine, choline, and procaine salts.

167. (previously presented) The composition of claim 1 or 164 wherein said drug alone has an aqueous solubility of less than 0.01 mg/mL at pH 1 to 8.

168. (previously presented) The composition of claim 1 or 164 wherein said drug and said polymer are combined without the use of a solvent.